Skip to content
OpenCapital
Get started

OS Therapies OSTX Q1 2026 Annual earnings

Reported May 18, 2026 · Before market open

Diluted EPS-$0.27Miss by $0.10
Revenue estimate$971.0K
EPS estimate-$0.17

Next report

Aug 17, 2026 (in a month)
Revenue estimate$511.0K
EPS estimate-$0.23

Financials

Q1 2026

Income statement

See full
Operating income-$10.2M-103%
Net income-$10.4M-168%
EPS (diluted)-$0.27-50.0%

Balance sheet

See full
Cash & equivalents$917.6K-69.1%
Total debt$20.0M—
Total equity-$10.8M-159%
Total assets$7.3M+71.7%

Cash flow

See full
Operating cash flow-$4.6M-32.6%

Valuation & ratios

Valuation

as of 07/10/26
See full
Market cap$76.61M+48.1%
Enterprise value$95.69M—

Returns & leverage

See full
Current ratio0.1×-1.1×

Versus estimates

Diluted EPS

Q1 2026-$0.27Miss by $0.10
Q4 2025-$0.37Miss by $0.23Q3 2025-$0.21Miss by $0.05Q2 2025-$0.19Miss by $0.04Q1 2025-$0.18Miss by $0.07Q4 2024-$0.24Miss by $0.10

Ask the moment OS Therapies reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did OS Therapies report Q1 2026 earnings?
OS Therapies (OSTX) reported Q1 2026 earnings on May 18, 2026 before market open.
What were OS Therapies's Q1 2026 revenue and EPS?
OS Therapies reported diluted EPS of $-0.27 for Q1 2026.
Did OS Therapies beat estimates in Q1 2026?
EPS missed the consensus estimate of $-0.17 by $0.10.
How did OS Therapies's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS declined 50.0% from $-0.18.
Where can I find OS Therapies's Q1 2026 SEC filings?
You can read the 10-K periodic report (0001213900-26-036629) directly on SEC EDGAR. The filing index links above go to sec.gov.